Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Impact of Socioeconomic Status and Distance from Treatment Center on Survival in Patients Receiving Remission Induction Therapy for Newly Diagnosed Acute Myelogenous Leukemia (AML).

Cristina Rodriguez, Rachid Baz, Rony Abou Jawde, Lisa Rybicki, Christopher Lowe, Matt Kalaycio, Anjali Advani, Ronald Sobecks, Mikkael A. Sekeres

Blood (2006) 108 (11): 1920.

https://doi.org/10.1182/blood.V108.11.1920.1920

Published: 2006

Journal Articles

Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC).

Rachid Baz, Cristina Rodriguez, Rony Abou Jawde, Lisa Rybicki, Matt Kalaycio, Anjali Advani, Ronald Sobecks, Mikkael A. Sekeres

Blood (2006) 108 (11): 4492.

https://doi.org/10.1182/blood.V108.11.4492.4492

Published: 2006

Journal Articles

c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.

Cristina Rodriguez, MD, Tao Jin, MS, Rony Abou Jawde, MD, Wael Saber, MD, Rachid Baz, MD, Eric His, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Mikkael Sekeres, MD, Anjali Advani, MD

Blood (2006) 108 (11): 4510.

https://doi.org/10.1182/blood.V108.11.4510.4510

Published: 2006

Journal Articles

CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Wael Saber, MD, Rony Abou-Jawde, MD, Eric Hsi, MD, Tao Jin, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Mikkael Sekeres, MD, Brad Pohlman, MD, Barbara L. Tripp, RN, Anjali Advani, MD

Blood (2005) 106 (11): 3292.

https://doi.org/10.1182/blood.V106.11.3292.3292

Published: 2005

Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM).

Rachid Baz, MD, Toni K. Choueiri, MD, Rony Abou Jawde, MD, Bridget McGowan, Yvette Ellis, Catherine Brand, Mohamad A. Hussein, MD

Blood (2005) 106 (11): 2559.

https://doi.org/10.1182/blood.V106.11.2559.2559

Published: 2005

NARROW

Impact of Socioeconomic Status and Distance from Treatment Center on Survival in Patients Receiving Remission Induction Therapy for Newly Diagnosed Acute Myelogenous Leukemia (AML).

Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC).

c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.

CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM).

Email alerts

ASH Publications

American Society of Hematology

Impact of Socioeconomic Status and Distance from Treatment Center on Survival in Patients Receiving Remission Induction Therapy for Newly Diagnosed Acute Myelogenous Leukemia (AML).

Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC).

c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.

CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only